Protection against experimental Helicobacter pylori infection after immunization with inactivated H. pylori whole-cell vaccines.
about
Sublingual immunization protects against Helicobacter pylori infection and induces T and B cell responses in the stomachVaccine against Helicobacter pylori: Inevitable approachToward the development of a stable, freeze-dried formulation of Helicobacter pylori killed whole cell vaccine adjuvanted with a novel mutant of Escherichia coli heat-labile toxin.HpaA is essential for Helicobacter pylori colonization in mice.Proinflammatory cytokine gene expression in the stomach correlates with vaccine-induced protection against Helicobacter pylori infection in mice: an important role for interleukin-17 during the effector phase.Who's Winning the War? Molecular Mechanisms of Antibiotic Resistance in Helicobacter pyloriLocalized suppression of inflammation at sites of Helicobacter pylori colonization.Systemic Th1 immunization of mice against Helicobacter pylori infection with CpG oligodeoxynucleotides as adjuvants does not protect from infection but enhances gastritis.Helicobacter pylori- inflammation, immunity and vaccines.A double mutant heat-labile toxin from Escherichia coli, LT(R192G/L211A), is an effective mucosal adjuvant for vaccination against Helicobacter pylori infection.M-cell targeting of whole killed bacteria induces protective immunity against gastrointestinal pathogens.Contribution of secretory antibodies to intestinal mucosal immunity against Helicobacter pylori.Antibody-mediated protection against infection with Helicobacter pylori in a suckling mouse model of passive immunity.Anti-Helicobacter pylori Properties of GutGard™.Current state and challenges in developing oral vaccines.The study of H. pylori putative candidate factors for single- and multi-component vaccine development.Catalytic features and eradication ability of antibody light-chain UA15-L against Helicobacter pylori.Down-regulation of epithelial IL-8 responses in Helicobacter pylori-infected duodenal ulcer patients depends on host factors, rather than bacterial factors.Natural killer cells and Helicobacter pylori infection: bacterial antigens and interleukin-12 act synergistically to induce gamma interferon production.Expression of UreB and HspA of Helicobacter pylori in silkworm pupae and identification of its immunogenicity.Absence of CD4+CD25+ regulatory T cells is associated with a loss of regulation leading to increased pathology in Helicobacter pylori-infected mice.Protease-activated receptor 1 suppresses Helicobacter pylori gastritis via the inhibition of macrophage cytokine secretion and interferon regulatory factor 5.The adjuvant effect of CpG oligodeoxynucleotide linked to the non-toxic B subunit of cholera toxin for induction of immunity against H. pylori in mice.Antigen-specific in vitro suppression of murine Helicobacter pylori-reactive immunopathological T cells by CD4CD25 regulatory T cells.Development of gastric adenocarcinoma in Mongolian gerbils after long-term infection with Helicobacter pylori.
P2860
Q24594741-90607118-4FD4-40F2-A1BA-F26FEE536E7BQ26752743-36E5E4A2-444C-4DD0-BFE7-FBBD925F607BQ33624306-38F90109-0EE4-4D33-9B02-9E4FD71CE369Q34334207-ED9382DA-6D91-43E0-80B8-6D6BDCB199B9Q34529454-8E9F0E2B-C0B9-430C-8477-4D44B4C48B02Q35104855-E85ECDE2-E214-4519-9DDA-366F640FA1D8Q35273091-CE3F6E9A-5F03-4A78-9EB7-0D5DF16D950AQ35550167-EBE5E385-C26C-4D5C-A68B-CB8A75917E00Q35583570-FB4F32CE-B154-4799-A2D3-AE2143E25216Q36826907-A33E1772-F97B-4FFD-BE57-121BEEC1E7EDQ37256573-A60D7AEF-292C-42B8-9BD9-EBAAB485630AQ37264684-2391CEC0-6479-4AB7-9955-0CE3C5FE1019Q37410270-99E9C2E7-5A71-4AF1-BEA5-456F1469D147Q37481544-D3A125AD-598F-4047-96DC-F5F09DEF6274Q39259629-BEC3554A-5A3F-4400-9B9C-62D3134F28C1Q39350897-696CB530-51EC-4056-970E-E8C481E2B9E2Q40155856-A9F58F37-4ABB-4152-8632-426DC37E0E57Q40447723-1DD206FE-0100-4040-986F-F13C3B6A217BQ41856661-2D6288C1-C890-43E8-81B8-6ACB2EB79A6FQ42022171-C5D06A0C-623A-4E18-9BBA-FB0A7374403CQ45111137-2CA7DC66-F2E1-4CBE-AD8B-D85EFFFC7E90Q45141825-C6A3601C-74F4-461B-81B1-5DDABAFE09E5Q46734851-2EE35F57-A470-4462-BAA8-B8431E3954D6Q47239334-EB7A3325-B7BA-4EBD-BA5A-BD62A3AE1343Q53364833-B8640A02-71F7-4098-941E-EAE80055043B
P2860
Protection against experimental Helicobacter pylori infection after immunization with inactivated H. pylori whole-cell vaccines.
description
2002 nî lūn-bûn
@nan
2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Protection against experimenta ...... H. pylori whole-cell vaccines.
@ast
Protection against experimenta ...... H. pylori whole-cell vaccines.
@en
Protection against experimenta ...... H. pylori whole-cell vaccines.
@nl
type
label
Protection against experimenta ...... H. pylori whole-cell vaccines.
@ast
Protection against experimenta ...... H. pylori whole-cell vaccines.
@en
Protection against experimenta ...... H. pylori whole-cell vaccines.
@nl
prefLabel
Protection against experimenta ...... H. pylori whole-cell vaccines.
@ast
Protection against experimenta ...... H. pylori whole-cell vaccines.
@en
Protection against experimenta ...... H. pylori whole-cell vaccines.
@nl
P2093
P2860
P1476
Protection against experimenta ...... H. pylori whole-cell vaccines.
@en
P2093
A-M Svennerholm
M Hjulström
S Raghavan
P2860
P304
P356
10.1128/IAI.70.11.6383-6388.2002
P407
P50
P577
2002-11-01T00:00:00Z